NASDAQ: VRNAVerona Pharma PLC Stock
$58.92+0.62 (+1.06%)
Updated Apr 17, 2025
VRNA Price
$58.92
Fair Value Price
$0.78
Market Cap
$5.01B
52 Week Low
$11.39
52 Week High
$70.40
P/E
-27.28x
P/B
24.48x
P/S
89.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$42.28M
Earnings
-$173.42M
Gross Margin
93.9%
Operating Margin
-330.16%
Profit Margin
-410.2%
Debt to Equity
1.32
Operating Cash Flow
-$122M
Beta
0.81
Next Earnings
Apr 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A
VRNA Overview
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VRNA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VRNA
Ranked#115 of 463
Ranked#115 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important VRNA news, forecast changes, insider trades & much more!
VRNA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VRNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRNA ($58.92) is overvalued by 7,476.32% relative to our estimate of its Fair Value price of $0.78 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VRNA ($58.92) is not significantly undervalued (7,476.32%) relative to our estimate of its Fair Value price of $0.78 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VRNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VRNA due diligence checks available for Premium users.
Valuation
VRNA fair value
Fair Value of VRNA stock based on Discounted Cash Flow (DCF)
Price
$58.92
Fair Value
$0.78
Overvalued by
7,476.32%
VRNA ($58.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VRNA ($58.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VRNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VRNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-27.28x
Industry
-177.72x
Market
27.98x
VRNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
24.48x
Industry
4.05x
VRNA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VRNA's financial health
Profit margin
Revenue
$36.7M
Net Income
-$33.8M
Profit Margin
-92.3%
VRNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VRNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$474.2M
Liabilities
$269.7M
Debt to equity
1.32
VRNA's short-term assets ($453.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRNA's short-term assets ($453.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VRNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.8M
Investing
-$535.0k
Financing
$94.2M
VRNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRNA vs Biotech Stocks
Verona Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.